What is William Blair's Forecast for Amgen FY2026 Earnings?

Amgen Inc. (NASDAQ:AMGN - Free Report) - Equities researchers at William Blair upped their FY2026 earnings per share (EPS) estimates for shares of Amgen in a research report issued on Monday, July 14th. William Blair analyst M. Phipps now anticipates that the medical research company will earn $21.67 per share for the year, up from their prior forecast of $21.62. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Amgen's current full-year earnings is $20.62 per share.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. The business had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The company's revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.96 earnings per share.

AMGN has been the topic of several other research reports. Piper Sandler reiterated an "overweight" rating and issued a $328.00 price target on shares of Amgen in a report on Friday, June 27th. Guggenheim started coverage on shares of Amgen in a research note on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 price objective on the stock. Wall Street Zen upgraded shares of Amgen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 18th. Mizuho upped their price target on shares of Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a report on Wednesday, May 7th. Finally, UBS Group reiterated a "neutral" rating and set a $315.00 price objective (down previously from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $307.82.

Amgen Stock Performance

Shares of AMGN traded down $0.77 during trading hours on Tuesday, reaching $298.25. 1,724,736 shares of the company traded hands, compared to its average volume of 2,836,377. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 8.70. The business has a fifty day moving average price of $284.80 and a 200-day moving average price of $288.65. Amgen has a 12-month low of $253.30 and a 12-month high of $346.85. The stock has a market capitalization of $160.37 billion, a P/E ratio of 27.21, a P/E/G ratio of 2.64 and a beta of 0.49.

Hedge Funds Weigh In On Amgen

Hedge funds and other institutional investors have recently made changes to their positions in the company. Wealth Preservation Advisors LLC acquired a new stake in shares of Amgen in the first quarter valued at approximately $25,000. First Pacific Financial raised its holdings in shares of Amgen by 304.5% during the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company's stock worth $28,000 after acquiring an additional 67 shares during the period. CBIZ Investment Advisory Services LLC increased its position in Amgen by 1,214.3% during the first quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company's stock worth $29,000 after purchasing an additional 85 shares during the last quarter. Pinney & Scofield Inc. purchased a new position in Amgen during the fourth quarter worth about $26,000. Finally, Activest Wealth Management increased its holdings in shares of Amgen by 3,433.3% during the 1st quarter. Activest Wealth Management now owns 106 shares of the medical research company's stock worth $33,000 after buying an additional 103 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Insider Activity

In related news, SVP Rachna Khosla sold 1,500 shares of Amgen stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the sale, the senior vice president directly owned 8,162 shares in the company, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.76% of the stock is currently owned by company insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.